Dauer W - Search Results

1

Predictive Big Data Analytics: A Study of Parkinson's Disease Using Large, Complex, Heterogeneous, Incongruent, Multi-Source and Incomplete Observations.

Dinov ID, Heavner B, Tang M, Glusman G, Chard K, Darcy M, Madduri R, Pa J, Spino C, Kesselman C, Foster I, Deutsch EW, Price ND, Van Horn JD, Ames J, Clark K, Hood L, Hampstead BM, Dauer W, Toga AW. Dinov ID, et al. Among authors: dauer w. PLoS One. 2016 Aug 5;11(8):e0157077. doi: 10.1371/journal.pone.0157077. eCollection 2016. PLoS One. 2016. PMID: 27494614 Free PMC article.

2

Model-based and Model-free Machine Learning Techniques for Diagnostic Prediction and Classification of Clinical Outcomes in Parkinson's Disease.

Gao C, Sun H, Wang T, Tang M, Bohnen NI, Müller MLTM, Herman T, Giladi N, Kalinin A, Spino C, Dauer W, Hausdorff JM, Dinov ID. Gao C, et al. Among authors: dauer w. Sci Rep. 2018 May 8;8(1):7129. doi: 10.1038/s41598-018-24783-4. Sci Rep. 2018. PMID: 29740058 Free PMC article.

3

α4β2^* Nicotinic Cholinergic Receptor Target Engagement in Parkinson Disease Gait-Balance Disorders.

Albin RL, Müller MLTM, Bohnen NI, Spino C, Sarter M, Koeppe RA, Szpara A, Kim K, Lustig C, Dauer WT. Albin RL, et al. Ann Neurol. 2021 Jul;90(1):130-142. doi: 10.1002/ana.26102. Epub 2021 May 26. Ann Neurol. 2021. PMID: 33977560 Free PMC article.

4

Endolysosomal dysfunction in Parkinson's disease: Recent developments and future challenges.

Kett LR, Dauer WT. Kett LR, et al. Mov Disord. 2016 Oct;31(10):1433-1443. doi: 10.1002/mds.26797. Mov Disord. 2016. PMID: 27619535 Free PMC article. Review.

5

Magic shotgun for Parkinson's disease?

Albin RL, Dauer WT. Albin RL, et al. Brain. 2014 May;137(Pt 5):1274-5. doi: 10.1093/brain/awu076. Brain. 2014. PMID: 24771397 No abstract available.

6

Genetic background modulates the phenotype of a mouse model of DYT1 dystonia.

Tanabe LM, Martin C, Dauer WT. Tanabe LM, et al. PLoS One. 2012;7(2):e32245. doi: 10.1371/journal.pone.0032245. Epub 2012 Feb 29. PLoS One. 2012. PMID: 22393392 Free PMC article.

7

The WD40 domain is required for LRRK2 neurotoxicity.

Jorgensen ND, Peng Y, Ho CC, Rideout HJ, Petrey D, Liu P, Dauer WT. Jorgensen ND, et al. PLoS One. 2009 Dec 24;4(12):e8463. doi: 10.1371/journal.pone.0008463. PLoS One. 2009. PMID: 20041156 Free PMC article.

8

LRRK2 Parkinson disease mutations enhance its microtubule association.

Kett LR, Boassa D, Ho CC, Rideout HJ, Hu J, Terada M, Ellisman M, Dauer WT. Kett LR, et al. Hum Mol Genet. 2012 Feb 15;21(4):890-9. doi: 10.1093/hmg/ddr526. Epub 2011 Nov 11. Hum Mol Genet. 2012. PMID: 22080837 Free PMC article.

9

Targeting the pedunculopontine nucleus in Parkinson's disease: Time to go back to the drawing board.

Albin RL, Surmeier DJ, Tubert C, Sarter M, Müller MLTM, Bohnen NI, Dauer WT. Albin RL, et al. Mov Disord. 2018 Dec;33(12):1871-1875. doi: 10.1002/mds.27540. Epub 2018 Nov 6. Mov Disord. 2018. PMID: 30398673 Free PMC article. Review. No abstract available.

10

Cholinergic system changes of falls and freezing of gait in Parkinson's disease.

Bohnen NI, Kanel P, Zhou Z, Koeppe RA, Frey KA, Dauer WT, Albin RL, Müller MLTM. Bohnen NI, et al. Ann Neurol. 2019 Apr;85(4):538-549. doi: 10.1002/ana.25430. Epub 2019 Mar 13. Ann Neurol. 2019. PMID: 30720884 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

108 results

Search Page

Filters